Covance rated at buy by Jefferies

Covance, Inc. was given a buy rating by Jefferies & Co., Inc. analyst David Windley after the company announced its second phase 1 acquisition. Covance acquired Radiant Research's phase 1 network of about 300 to 350 beds and $25 million in revenue for $65 million. Shares of the Princeton, N.J., drug development services company were up 46 cents, or 0.73%, at $63.11 on volume of 809,100 shares versus the three-month running average of 440,994 shares. (NYSE: CVD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.